Search | Page 4 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Personalized medicine for MDS

    ... patients into “lower-risk” disease, where improvement in blood counts is the main goal of therapy, and “higher-risk” disease, where ... agents (ESAs) as a single agent reduces transfusion dependence in about 50% of lower-risk MDS patients.  However, no ...

    Research Review last updated 05/02/2016 - 9:44am.

  2. AAMDSIF Stephen and Joanna Janowiak Research Fund

    ... persisted, so she  returned to the doctor.  Various blood tests were done.  Again, she went home, and the next day, she received ... call that she needed to go to the hospital for a blood transfusion immediately. She first called her husband  Steve with the ...

    Research Fund last updated 06/08/2017 - 4:57pm.

  3. Polymorphism of the complement receptor 1 gene correlates with hematological response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria

    ... the response is variable and some patients remain red blood cell transfusion -dependent. In 72 patients with hemolytic Paroxysmal Nocturnal ...

    Research Article last updated 09/26/2013 - 3:28pm.

  4. Brittany Springer – Aplastic Anemia Patient “Just Focused on Beating It”

    ... due to my work and school schedule. She ran a regular CBC blood test.  The next day,  I was surprised to see I had missed a call ... she thought I might have leukemia. She told me I needed a transfusion (my platelet count was 56). I was so upset I could not ...

    Patient Chronicle last updated 04/29/2016 - 3:29pm.

  5. Eltrombopag Added to IST Yields Encouraging Results

    ... we had only hoped eltrombopag would improve the platelet transfusion frequency in patients who had not adequately responded to ... in platelet counts but also noticed recovering red and white blood cells numbers. Although the magnitude of the response was somewhat ...

    Interview last updated 05/24/2017 - 7:44am.

  6. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

    Journal Title:  Blood Primary Author:  Fenaux P ... the efficacy and safety of lenalidomide in 205 RBC transfusion-dependent patients with IPSS Low-/Intermediate-1-risk del5q31 ...

    Research Article last updated 07/28/2014 - 9:04am.

  7. Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes

    ... Overall Response (complete or partial remission, red blood cell [RBC] or platelet transfusion independence [TI], or hematologic improvement, (IWG 2006) was ...

    Research Article last updated 12/09/2015 - 8:56am.

  8. The immunomodulatory agents lenalidomide and thalidomide for treatment of the myelodysplastic syndromes: A clinical practice guideline.

    ... with the aging population. Treatment includes red blood cell transfusion for anemia . The immunomodulatory agents (imids) ...

    Research Article last updated 10/01/2012 - 10:04am.

  9. AAMDSIF Summer Fellowship Grant Program

    ... (BM) characterized by profound decrease of the number of red blood cells, white blood cells, and platelets in the blood stream, leading to ... the elderly. Currently, treatment includes blood transfusion to treat the anemia, and toxic chemotherapies that can deepen ...

    Page last updated 05/17/2017 - 1:29pm.

  10. Jeff Paccione: “Don’t worry, I’m not going anywhere.”

    ... on Jeff’s retinas, he immediately told Jeff to get blood work and so we rushed to his doctor.   The 7:00 a.m. phone call the ... waiting room before Jeff received platelets and a blood transfusion , he leaned over to me and quietly assured me, “Don’t worry, ...

    Patient Chronicle last updated 05/23/2017 - 10:40am.